Metoprololo Hexal (Metoprolol Tartrate)

Metoprolol tartrate selectively blocks β1‑adrenergic receptors in the heart, preventing catecholamines from stimulating these receptors. This action slows the heart rate, reduces the force of contraction, and lowers cardiac output. It also suppresses renin release from the kidneys, decreasing systemic vascular resistance. The combined effects lower blood pressure and myocardial oxygen demand, which underpins its therapeutic use.

The exact dose of Metoprololo Hexal is individualized by the prescribing clinician based on the patient’s medical condition, severity, age, renal and hepatic function, and response to therapy. Dosage adjustments may be required for elderly patients or those with organ impairment. Patients should follow the prescriber’s instructions and not alter the dose without medical advice.

The safety of Metoprololo Hexal in pregnancy and lactation has not been definitively established, and the product is listed with an unknown pregnancy category. Healthcare providers must weigh potential benefits against possible risks to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatments or close monitoring with their physician.

To order Metoprololo Hexal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify institutional credentials, provide pricing, confirm availability, arrange shipping (including any required temperature control), and handle import documentation.

Metoprololo Hexal (metoprolol tartrate) is a selective β1‑blocker, offering cardiac‑specific effects with fewer respiratory side effects compared with non‑selective agents like propranolol. Compared with atenolol, metoprolol has a shorter half‑life and may require multiple daily doses, but it provides more consistent heart‑rate control. Choice of beta blocker depends on patient comorbidities, dosing convenience, and physician preference.

Metoprololo Hexal tablets should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original blister pack or container, protect it from moisture, direct sunlight, and extreme heat. Do not store in the bathroom or near a kitchen sink. Proper storage helps maintain tablet potency throughout its shelf life.

Metoprololo Hexal is taken orally as a tablet. The tablet should be swallowed whole with a full glass of water, preferably at the same times each day to maintain steady blood levels. It can be taken with or without food, but patients should follow the prescriber’s instructions regarding timing relative to meals.

Serious risks include severe bradycardia, heart block, marked hypotension, bronchospasm in patients with asthma or COPD, and acute heart‑failure exacerbation. Rare but critical reactions such as allergic anaphylaxis, depression, or profound fatigue may also occur. Patients should seek immediate medical attention if they experience fainting, chest pain, severe shortness of breath, or signs of an allergic reaction.

Metoprololo Hexal is contraindicated in patients with severe bradycardia (heart rate < 45 bpm), second‑ or third‑degree atrioventricular block, cardiogenic shock, overt heart‑failure decompensation, or uncontrolled asthma/COPD where bronchospasm could be life‑threatening. It should also be avoided in individuals with known hypersensitivity to metoprolol or any excipients in the tablet formulation.